In today’s session Alexion Pharmaceuticals, Inc. (ALXN) registered an unusually high (149) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious ALXN increase. With 149 contracts traded and 8294 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: ALXN161021C00130000 closed last at: $1.25 or 3.8% down. About 141,859 shares traded hands. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 13.34% since March 9, 2016 and is downtrending. It has underperformed by 20.76% the S&P500.
Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on November, 3. They expect $1.04 EPS, up 11.83% or $0.11 from last year’s $0.93 per share. ALXN’s profit will be $225.29M for 29.21 P/E if the $1.04 EPS becomes a reality. After $0.93 actual EPS reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.83% EPS growth.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage
Out of 18 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 13 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 72% are positive. $257 is the highest target while $82 is the lowest. The $175.13 average target is 44.14% above today’s ($121.5) stock price. Alexion Pharmaceuticals Inc. has been the topic of 36 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, September 20 by Citigroup. Wedbush initiated it with “Neutral” rating and $132 target price in Friday, September 23 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Neutral” rating given on Thursday, January 7 by BTIG Research. Brean Capital maintained it with “Buy” rating and $221 target price in Friday, July 31 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Outperform” rating by BMO Capital Markets on Friday, April 29. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Equal Weight” rating by Barclays Capital on Monday, September 14. The company was initiated on Tuesday, September 1 by Raymond James. Leerink Swann maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Monday, September 26. Leerink Swann has “Outperform” rating and $211 price target. The stock has “Buy” rating given by SunTrust on Thursday, January 7. The rating was maintained by Stifel Nicolaus on Friday, December 11 with “Buy”.
According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”
Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.42, from 0.77 in 2016Q1. The ratio improved, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.
Virginia Retirement Et Al holds 0.02% or 12,100 shares in its portfolio. Webster Financial Bank N A has 7,000 shares for 0.12% of their US portfolio. Cetera Advisor Llc last reported 0.01% of its portfolio in the stock. Guggenheim Limited Company holds 440,304 shares or 0.16% of its portfolio. Mycio Wealth Prns Ltd Liability holds 0% or 16 shares in its portfolio. Blackrock Ltd Llc has 809,908 shares for 0.12% of their US portfolio. Utah Retirement last reported 0.12% of its portfolio in the stock. Planning reported 3,276 shares or 0.03% of all its holdings. Pacad Invest Ltd reported 8,393 shares or 0.14% of all its holdings. Balyasny Asset Management Ltd Limited Liability Company last reported 0.07% of its portfolio in the stock. Moreover, Employees Retirement Of Texas has 0.11% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 70,938 shares. Synovus Finance reported 15,667 shares or 0.04% of all its holdings. Meeder Asset Management Inc holds 0.07% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 6,121 shares. Thrivent Fincl For Lutherans holds 0.35% or 624,860 shares in its portfolio. Huntington Retail Bank accumulated 0% or 560 shares.
Insider Transactions: Since May 13, 2016, the stock had 0 insider purchases, and 17 selling transactions for $3.95 million net activity. Hallal David sold $45,530 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Monday, August 8. On Tuesday, August 30 Carmichael Clare sold $127,760 worth of the stock or 1,000 shares. Sinha Vikas sold $37,988 worth of stock. On Monday, August 8 BELL LEONARD sold $138,511 worth of the stock or 1,010 shares. Shares for $125,940 were sold by Thiel Carsten on Tuesday, September 6. Wagner Heidi L sold $30,445 worth of stock or 222 shares. Moriarty John B had sold 918 shares worth $124,591.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $26.32 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has a 307.7 P/E ratio. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment.
ALXN Company Profile
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.
More recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Businesswire.com which released: “Alexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday …” on October 10, 2016. Also Prnewswire.com published the news titled: “Biotech Stocks on Investors’ Radar — Alexion Pharma, PDL BioPharma, BioCryst …” on October 12, 2016. Seekingalpha.com‘s news article titled: “Alexion Pharma Receives $194 Price Target” with publication date: September 29, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.